Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis
Conditions
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
ALX-101 Gel 5% and ALX-101 Gel Vehicle
Locations
35
United States
Ralexar Investigational Site 35
Anniston, Alabama, United States
Ralexar Investigational Site 21
Birmingham, Alabama, United States
Ralexar Investigational Site 18
Laguna Hills, California, United States
Ralexar Investigational Site 23
Los Angeles, California, United States
Ralexar Investigational Site 24
Oceanside, California, United States
Ralexar Investigational Site 34
San Diego, California, United States
Start Date
April 26, 2017
Primary Completion Date
June 29, 2018
Completion Date
June 29, 2018
Last Updated
October 25, 2018
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Ralexar Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions